HN2009003357A - Nuevos compuesto ligandos del receptor de la adenosina a3 - Google Patents
Nuevos compuesto ligandos del receptor de la adenosina a3Info
- Publication number
- HN2009003357A HN2009003357A HN2009003357A HN2009003357A HN2009003357A HN 2009003357 A HN2009003357 A HN 2009003357A HN 2009003357 A HN2009003357 A HN 2009003357A HN 2009003357 A HN2009003357 A HN 2009003357A HN 2009003357 A HN2009003357 A HN 2009003357A
- Authority
- HN
- Honduras
- Prior art keywords
- receiver
- ligandos
- adenosine
- new compound
- solvatos
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A LOS LIGANDOS DEL RECEPTOR DE ADENOSIMA A3, DE FORMULA GENERAL I) DENTRO DE ELLOS LOS FAVORABLES A LOS ANTAGONISTAS, SUS SALES, SOLVATOS, N-OXIDOS E ISOMERICOS, A LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN GENERAL I) SUS SALES, SOLVATOS, N- OXIDOS E ISOMEROS, A LA PREPARACION DE LOS COMPUESTOS DE FORMULA GENERAL I) SUS SALES, SOLVATOS, N- OXIDOS E ISOMEROS , ASI COMO A LOS NUEVOS INTERMEDIARIOS DE FORMULA GENERAL. (II), (VI), (XI), (XII), Y (XV) Y A LA PREPARACION DE ELLOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0700395A HUP0700395A2 (en) | 2007-06-07 | 2007-06-07 | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN2009003357A true HN2009003357A (es) | 2013-08-12 |
Family
ID=89987565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2009003357A HN2009003357A (es) | 2007-06-07 | 2009-12-04 | Nuevos compuesto ligandos del receptor de la adenosina a3 |
Country Status (44)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101722289B1 (ko) | 2009-07-08 | 2017-03-31 | 데르미라 (캐나다), 인코포레이티드 | 피부과 질환 또는 증상의 치료에 유용한 ｔｏｆａ 유사체 |
| FR3053968A1 (fr) * | 2016-07-13 | 2018-01-19 | Biomerieux | Reactifs pour la protection reversible de molecules biologiques |
| CA3037588C (en) * | 2016-09-24 | 2022-07-12 | Kbp Biosciences Co., Ltd. | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof |
| CR20230030A (es) | 2018-02-27 | 2023-03-10 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b (divisional 2020-0441) |
| MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
| MX2021000116A (es) | 2018-07-05 | 2021-03-29 | Incyte Corp | Derivados de pirazina fusionados como inhibidores de a2a/a2b. |
| PE20211768A1 (es) | 2018-11-30 | 2021-09-07 | Merck Sharp & Dohme | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso |
| BR112021011948A2 (pt) | 2018-12-20 | 2021-09-08 | Incyte Corporation | Compostos de imidazopiridazina e imidazopiridina e usos dos mesmos |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479759A (en) * | 1974-11-23 | 1977-07-13 | Lepetit Spa | Heterocyclic fused derivatives of indole and quinoline |
| GR76063B (es) * | 1981-04-03 | 1984-08-03 | Roussel Uclaf | |
| ZA836701B (en) * | 1982-10-01 | 1984-10-31 | Roussel Uclaf | Imidazo(1,2-a)quinolines |
| GB0108475D0 (en) | 2001-04-04 | 2001-05-23 | Merck Sharp & Dohme | New compounds |
| CN1257160C (zh) * | 2001-05-31 | 2006-05-24 | 赛诺菲-安万特公司 | 氨基喹啉衍生物和它们的作为腺苷a3配体的应用 |
| US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| AU2002361374A1 (en) | 2001-12-21 | 2003-07-09 | JSW-Research Forschungslabor GmbH% | Pyrazolyl-substituted triazoloquinoxalines |
| HUP0105406A3 (en) * | 2001-12-21 | 2003-12-29 | Sanofi Aventis | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| HUP0105407A3 (en) * | 2001-12-21 | 2004-04-28 | Sanofi Aventis | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| WO2005009969A1 (en) * | 2003-07-31 | 2005-02-03 | Sanofi-Aventis | Aminoquinoline derivatives and their use as adenosine a3 ligands |
-
2007
- 2007-06-07 HU HU0700395A patent/HUP0700395A2/hu unknown
-
2008
- 2008-02-06 UA UAA200913976A patent/UA99463C2/ru unknown
- 2008-06-02 NZ NZ581186A patent/NZ581186A/en not_active IP Right Cessation
- 2008-06-02 AT AT08762666T patent/ATE502016T1/de active
- 2008-06-02 DK DK08762666.9T patent/DK2167470T3/da active
- 2008-06-02 KR KR1020107000342A patent/KR20100031610A/ko not_active Ceased
- 2008-06-02 DE DE602008005589T patent/DE602008005589D1/de active Active
- 2008-06-02 CA CA002689612A patent/CA2689612A1/en not_active Abandoned
- 2008-06-02 SI SI200830255T patent/SI2167470T1/sl unknown
- 2008-06-02 ME MEP-2009-340A patent/ME00958B/me unknown
- 2008-06-02 BR BRPI0812257-1A2A patent/BRPI0812257A2/pt not_active IP Right Cessation
- 2008-06-02 HR HR20110332T patent/HRP20110332T1/hr unknown
- 2008-06-02 AU AU2008259534A patent/AU2008259534B2/en not_active Ceased
- 2008-06-02 JP JP2010510891A patent/JP5487100B2/ja not_active Expired - Fee Related
- 2008-06-02 WO PCT/HU2008/000063 patent/WO2008149168A1/en not_active Ceased
- 2008-06-02 PL PL08762666T patent/PL2167470T3/pl unknown
- 2008-06-02 EP EP08762666A patent/EP2167470B1/en active Active
- 2008-06-02 MY MYPI20095180A patent/MY148654A/en unknown
- 2008-06-02 ES ES08762666T patent/ES2363672T3/es active Active
- 2008-06-02 CN CN2008800191923A patent/CN101679272B/zh not_active Expired - Fee Related
- 2008-06-02 PT PT08762666T patent/PT2167470E/pt unknown
- 2008-06-02 MX MX2009013209A patent/MX2009013209A/es active IP Right Grant
- 2008-06-02 RU RU2009149518/04A patent/RU2489432C2/ru not_active IP Right Cessation
- 2008-06-05 PE PE2008000960A patent/PE20090325A1/es not_active Application Discontinuation
- 2008-06-05 AR ARP080102391A patent/AR066873A1/es not_active Application Discontinuation
- 2008-06-05 PA PA20088782901A patent/PA8782901A1/es unknown
- 2008-06-05 JO JO2008263A patent/JO2689B1/en active
- 2008-06-05 CL CL200801648A patent/CL2008001648A1/es unknown
- 2008-06-06 TW TW097121025A patent/TWI424998B/zh not_active IP Right Cessation
- 2008-06-06 UY UY31130A patent/UY31130A1/es not_active Application Discontinuation
-
2009
- 2009-11-13 TN TNP2009000482A patent/TN2009000482A1/fr unknown
- 2009-11-20 GT GT200900301A patent/GT200900301A/es unknown
- 2009-11-23 ZA ZA2009/08280A patent/ZA200908280B/en unknown
- 2009-11-24 SV SV2009003420A patent/SV2009003420A/es unknown
- 2009-12-02 IL IL202471A patent/IL202471A0/en unknown
- 2009-12-03 NI NI200900210A patent/NI200900210A/es unknown
- 2009-12-04 DO DO2009000276A patent/DOP2009000276A/es unknown
- 2009-12-04 US US12/631,139 patent/US8338411B2/en not_active Expired - Fee Related
- 2009-12-04 HN HN2009003357A patent/HN2009003357A/es unknown
- 2009-12-04 EC EC2009009783A patent/ECSP099783A/es unknown
- 2009-12-16 CR CR11171A patent/CR11171A/es unknown
-
2010
- 2010-01-06 CO CO10001036A patent/CO6270233A2/es active IP Right Grant
- 2010-01-07 MA MA32498A patent/MA31738B1/fr unknown
-
2011
- 2011-05-30 CY CY20111100519T patent/CY1111644T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2009003357A (es) | Nuevos compuesto ligandos del receptor de la adenosina a3 | |
| UY31260A1 (es) | Compuestos de pirazol, composiciones conteniendolos y aplicaciones. | |
| PH12012502284A1 (en) | Antiviral nucleoside analogs | |
| NI200900032A (es) | Compuestos de pirido (2, 3-d) pirimidinonay su uso como inhibidores de pi3 | |
| ECSP11011517A (es) | Compuestos antivirales | |
| CR9814A (es) | Derivados de carboxamida como antagonistas del receptor muscarinico | |
| UY31048A1 (es) | Nuevos compuestos de pirimidina y usos de los mismos | |
| DOP2011000123A (es) | Nuevos compuestos halosustituidos | |
| GT200600074A (es) | 5-alcoxialquil-6-alquil-7-amino-azolopirimidinas, un procedimiento para su obtención y el uso de las mismas para combatir hongos nocivos, así como procuctos que las mismas contienen | |
| CR20120264A (es) | Compuestos | |
| CO6351723A2 (es) | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1 | |
| CR10497A (es) | Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38 | |
| MX2010001837A (es) | Derivados de 4-pirimidinasulfamida. | |
| UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
| CO6531479A2 (es) | Derivados de espirolactama y uso de los mismos | |
| CR11828A (es) | Compuestos novedosos activos como antagonistas de receptor muscarínico | |
| CR11392A (es) | Derivados de pirazol como inhibidores de 5-lo | |
| CR9574A (es) | Potenciadores del receptor ampa | |
| CR9595A (es) | Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona | |
| UY31338A1 (es) | Compuestos novedosos activos como antagonistas de receptores muscarinicos | |
| CU23564A3 (es) | Derivados de carboxamida como antagonistas del receptor muscarínico | |
| CU20110003A7 (es) | Compuestos novedosos activos como antagonistas de receptor muscarínico |